2015 BPD Header

Cambridge Healthtech Institute’s 4th Annual
High-Concentration Protein Formulations:
Formulation, Manufacturing, Analytics, High Viscosity, Aggregation, Devices and Delivery
August 5-6, 2015
Part of CHI's 7th Annual The Bioprocessing Summit

August 3-7, 2015 | Westin Copley Place Hotel | Boston, Massachusetts


At higher concentrations, proteins or antibodies exhibit characteristic problems including aggregation, precipitation, gelation, and increased viscosity. Development of these high-concentration protein formulations results in several manufacturing, stability, analytical, and delivery challenges. The popular High-Concentration Protein Formulations conference will feature informative, high quality case studies and successful strategies to overcome the problems you are facing with development and delivery of high-concentration formulations. We invite you to attend to learn from and network with the leading experts from around the world.


Preliminary Agenda 


PROTEIN- PROTEIN INTERACTIONS

Protein-Protein Solvation in High-Concentration Solutions

Thomas Laue, Ph.D., Professor, Biochemistry and Molecular Biology; Director, Biomolecular Interaction Technologies Center (BITC), University of New Hampshire


UNDERSTANDING & DEALING WITH VISCOSITY IN HIGH-CONCENTRATION PROTEIN FORMULATIONS

Viscosity in High-Concentration Protein Formulations

Thomas Palm, Ph.D., Senior Research Investigator II, Drug Product Science and Technology, Bristol-Myers Squibb Co.

Cluster Formation in Dense Protein Solutions and Its Implications to Solution Viscosity

Yun Liu, Ph.D., Research Associate Professor/Instrument Scientist, Chemical & Bimolecular Engineering/Center for Neutron Research, University of Delaware/National Institute of Standards and Technology


FORMULATION & CMC CHALLENGES OF HIGH-CONCENTRATION PROTEIN FORMULATIONS

HESylation® - A Versatile Polymer Modification Technology Enabling High-Concentration Protein Formulations

Thomas Hey, Ph.D., Director, Biochemistry, Innovation Center Complex Formulations, Fresenius Kabi Deutschland GmbH

Drug Product Design and High Concentration Formulation Development

Bruce Kerwin, Ph.D., Head, Drug Product Design, Just, Inc.

CMC Strategies on Scaling Up and Down for High-Concentration Protein formulations

Jamie Tsung, Ph.D., Principal Scientist, Momenta Pharmaceuticals, Inc.


ANALYTICAL TOOLS FOR HIGH-CONCENTRATION PROTEIN FORMULATIONS

Determination of Low Levels of Polysorbates in High Concentration Drug Substances and Drug Products

Shiranthi Jayawickreme, Ph.D., Associate Director, Analytical Development, Biogen Idec

Analytical Challenges with High-Concentration Protein Formulations

Michael S. Marlow, Ph.D., Senior Staff Scientist, Protein Biochemistry, Regeneron Pharmaceuticals, Inc.


DELIVERY & DEVICE CHALLENGES IN HIGH-CONCENTRATION/HIGH VOLUME PROTEIN FORMULATIONS

Reconstitution of Highly Concentrated Protein Formulations

Bakul Bhatnagar, Ph.D., Principal Scientist, Formulation & Process Development, Pfizer, Inc.

Device & Formulation – Two Inseparable Aspects of a Successful Product

Jan Jezek, Ph.D., CSO, Development, Arecor Ltd.




For more details on the conference, please contact:
Nandini Kashyap
Conference Director
Phone: 781-972-5406
Email: nkashyap@healthtech.com 

For exhibit & sponsorship opportunities, please contact: 

Companies A-K:
Elizabeth Lemelin
Business Development Manager
Phone: 781-972-1342
Email: elemelin@healthtech.com 

Companies L-Z:
Sherry Johnson
Business Development Manager
Phone: 781-972-1359
Email: sjohnson@healthtech.com